Investor Says Biotech Co. Hid Blood Treatment Funding Woes
Israeli biotechnology company BioLine misled the public and its shareholders about its financing shortfalls for a new blood therapy, then ultimately caused a 33% stock drop when it made moves to...To view the full article, register now.
Already a subscriber? Click here to view full article